awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q42796997-896D5D27-9F9F-46AE-9054-46C2CA33B6FD
Q42796997-896D5D27-9F9F-46AE-9054-46C2CA33B6FD
BestRank
Statement
http://www.wikidata.org/entity/statement/Q42796997-896D5D27-9F9F-46AE-9054-46C2CA33B6FD
Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study.
P2860
Q42796997-896D5D27-9F9F-46AE-9054-46C2CA33B6FD
BestRank
Statement
http://www.wikidata.org/entity/statement/Q42796997-896D5D27-9F9F-46AE-9054-46C2CA33B6FD
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
848a5c12d5bdc9d4b192d780ba63bacb7a45b12d
P2860
Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.